The Benzoylpiperidine Fragment As a Privileged Structure in Medicinal Chemistry: A Comprehensive Review

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 May 11

PMID 38731421

Authors

Giulia Bononi

Chiara Lonzi

Tiziano Tuccinardi

Filippo Minutolo

Carlotta Granchi

Affiliations

Soon will be listed here.

Abstract

The phenyl(piperidin-4-yl)methanone fragment (here referred to as the benzoylpiperidine fragment) is a privileged structure in the development of new drugs considering its presence in many bioactive small molecules with both therapeutic (such as anti-cancer, anti-psychotic, anti-thrombotic, anti-arrhythmic, anti-tubercular, anti-parasitic, anti-diabetic, and neuroprotective agents) and diagnostic properties. The benzoylpiperidine fragment is metabolically stable, and it is also considered a potential bioisostere of the piperazine ring, thus making it a feasible and reliable chemical frame to be exploited in drug design. Herein, we discuss the main therapeutic and diagnostic agents presenting the benzoylpiperidine motif in their structure, covering articles reported in the literature since 2000. A specific section is focused on the synthetic strategies adopted to obtain this versatile chemical portion.

References

Bowen W . Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv. 2000; 74(2-3):211-8. DOI: 10.1016/s0031-6865(99)00034-5. View

John C, Gulden M, Li J, Bowen W, McAfee J, Thakur M . Synthesis, in vitro binding, and tissue distribution of radioiodinated 2-[125I]N-(N-benzylpiperidin-4-yl)-2-iodo benzamide, 2-[125I]BP: a potential sigma receptor marker for human prostate tumors. Nucl Med Biol. 1998; 25(3):189-94. DOI: 10.1016/s0969-8051(97)00168-6. View

Mulvihill M, Nomura D . Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2012; 92(8-9):492-7. PMC: 3594462. DOI: 10.1016/j.lfs.2012.10.025. View

Zhong Y, Gao Y, Xu Y, Qi C, Wu B . Synthesis of Novel Aryloxyethylamine Derivatives and Evaluation of Their in Vitro and in Vivo Neuroprotective Activities. Chem Biodivers. 2020; 17(9):e2000431. DOI: 10.1002/cbdv.202000431. View

Marino M, Knutsen L, Williams M . Emerging opportunities for antipsychotic drug discovery in the postgenomic era. J Med Chem. 2008; 51(5):1077-107. DOI: 10.1021/jm701094q. View

Granchi C, Rizzolio F, Palazzolo S, Carmignani S, Macchia M, Saccomanni G . Structural Optimization of 4-Chlorobenzoylpiperidine Derivatives for the Development of Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors. J Med Chem. 2016; 59(22):10299-10314. DOI: 10.1021/acs.jmedchem.6b01459. View

Li Q, Chai L, Dong G, Zhang X, Du L . NBD-Based Environment-Sensitive Fluorescent Probes for the Human Ether-a-Go-Go-Related Gene Potassium Channel. Front Mol Biosci. 2021; 8:666605. PMC: 8160426. DOI: 10.3389/fmolb.2021.666605. View

Bourrie B, Bribes E, Derocq J, Vidal H, Casellas P . Sigma receptor ligands: applications in inflammation and oncology. Curr Opin Investig Drugs. 2004; 5(11):1158-63. View

van Rossum J . The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966; 160(2):492-4. View

10.

Poulie C, Liu N, Jensen A, Bunch L . Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT/mGlu Receptor Complex. J Med Chem. 2020; 63(17):9928-9949. DOI: 10.1021/acs.jmedchem.0c01058. View

11.

Li D, Gao N, Zhu N, Lin Y, Li Y, Chen M . Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB. Bioorg Med Chem Lett. 2015; 25(22):5178-81. DOI: 10.1016/j.bmcl.2015.09.072. View

12.

Kolb P, Rosenbaum D, Irwin J, Fung J, Kobilka B, Shoichet B . Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U S A. 2009; 106(16):6843-8. PMC: 2672528. DOI: 10.1073/pnas.0812657106. View

13.

Tu Z, Zhang X, Jin H, Yue X, Padakanti P, Yu L . Synthesis and biological characterization of a promising F-18 PET tracer for vesicular acetylcholine transporter. Bioorg Med Chem. 2015; 23(15):4699-4709. PMC: 4524497. DOI: 10.1016/j.bmc.2015.05.058. View

14.

Deau E, Robin E, Voinea R, Percina N, Satala G, Finaru A . Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [(18)F]-PET Imaging in a Primate Brain. J Med Chem. 2015; 58(20):8066-96. DOI: 10.1021/acs.jmedchem.5b00874. View

15.

Yadav V, Boshoff H, Trifonov L, Roma J, Ioerger T, Barry 3rd C . Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents. ACS Med Chem Lett. 2023; 14(9):1275-1283. PMC: 10510505. DOI: 10.1021/acsmedchemlett.3c00295. View

16.

Pollak M . Targeting oxidative phosphorylation: why, when, and how. Cancer Cell. 2013; 23(3):263-4. DOI: 10.1016/j.ccr.2013.02.015. View

17.

Elzinga G, Raviglione M, Maher D . Scale up: meeting targets in global tuberculosis control. Lancet. 2004; 363(9411):814-9. DOI: 10.1016/S0140-6736(04)15698-5. View

18.

Jenkins Y, Sun T, Markovtsov V, Foretz M, Li W, Nguyen H . AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes. PLoS One. 2013; 8(12):e81870. PMC: 3855387. DOI: 10.1371/journal.pone.0081870. View

19.

Dobrzyn A, Ntambi J . Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev. 2005; 6(2):169-74. DOI: 10.1111/j.1467-789X.2005.00177.x. View

20.

Tuccinardi T, Granchi C, Rizzolio F, Caligiuri I, Battistello V, Toffoli G . Identification and characterization of a new reversible MAGL inhibitor. Bioorg Med Chem. 2014; 22(13):3285-91. DOI: 10.1016/j.bmc.2014.04.057. View